Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by University of Miami
Sponsor:
Collaborator:
CSL Behring
Information provided by (Responsible Party):
Michael Campos, MD, University of Miami
ClinicalTrials.gov Identifier:
NCT01669421
First received: August 14, 2012
Last updated: January 13, 2015
Last verified: January 2015
  Purpose

The current treatment of individuals with alpha-1 antitrypsin deficiency (AATD) who develop lung disease (COPD) is the administration of intravenous purified alpha-1 antitrypsin (augmentation therapy) at a fixed dose of 60 mg/kg per week. This dose aims at increasing the deficient AAT serum levels just above a predetermined "safety threshold" of 11 uM. However, normal levels of AAT are between 25-50 uM.

AAT has shown not only to inhibit lung proteases such as neutrophil elastase, but also to modulate inflammation. Given that many subjects with AATD who receive augmentation therapy still have significant lung disease and inflammation, this study will evaluate whether doubling the dose to 120 mg/kg/week has an effect in decreasing lung inflammation.

Only the dosing of 60 mg/kg /week has received FDA approval. FDA has granted an IND number to this study to test the higher dose of 120 mg/kg/week.

The study will evaluate systemic (serum) and pulmonary (bronchoscopy samples)markers of inflammation in 3 phases: standard dose (4 weeks), double dose (4 weeks) and standard dose (4 weeks).


Condition Intervention Phase
Alpha 1 Antitrypsin Deficiency
Drug: Alpha-1 Antitrypsin (human)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency.

Resource links provided by NLM:


Further study details as provided by University of Miami:

Primary Outcome Measures:
  • CHANGES IN CYTOKINE PROFILE IN BRONCHOALVEOLAR LAVAGE [ Time Frame: at 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
    - Inflammatory markers: multiple cytokine panels using bead technology (Luminex) for: IL-1, IL-2, IL8, IL6, GM-CSF, TNF alpha, MCP-1, VEGF, RANTES. In addition, LTB4 will be measured by ELISA.


Secondary Outcome Measures:
  • CHANGES IN SERUM INFLAMMATORY MARKERS [ Time Frame: At 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
    We will measure C-reactive protein and multiple cytokine panels using bead technology (Luminex)for: IL-1, IL-2, IL8, IL6, GM-CSF, TNF alpha, MCP-1, VEGF, RANTES.

  • EFFECT OF DOUBLE DOSE ZEMAIRA ON ELASTIN DEGRADATION [ Time Frame: Weeks 4, 8 and 12 ] [ Designated as safety issue: No ]
    Desmosine and isodesmosine levels in plasma and BAL

  • EFFECT OF DOUBLE DOSE ZEMAIRA ON NEUTROPHIL APOPTOSIS AND MIGRATION [ Time Frame: Weeks 4, 8 and 12 ] [ Designated as safety issue: No ]
    Neutrophil apoptosis and migration assays in PMN obtained at the end of each phase.

  • CHANGES IN NEUTROPHILIC LUNG INFILTRATION [ Time Frame: 4, 8, 12 weeks ] [ Designated as safety issue: No ]
    Neutrophil % in BAL and endobronchial biopsies

  • NUMBER OF ADVERSE EVENTS REPORTED [ Time Frame: throughout the study ] [ Designated as safety issue: Yes ]
    Collected by weekly questionnaires

  • CHANGES IN METABOLIC AND COAGULATION PROFILES [ Time Frame: throughout the study ] [ Designated as safety issue: Yes ]
    Serial measures of CBC, chemistry panel and coagulation panels


Estimated Enrollment: 20
Study Start Date: July 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alpha-1 Antitrypsin (human)
Alpha-1 Antitrypsin (human) 120 mg per kg per week for 4 weeks
Drug: Alpha-1 Antitrypsin (human)
Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Other Names:
  • Zemaira
  • Alpha-1 proteinase inhibitor (human)

Detailed Description:

This is a pilot study to test the effect of double dose augmentation therapy with Zemaira (CSL Behring) on lung inflammation, compared with standard doses of 60 mg/kg/week.

Our hypothesis is that some patients with AATD receiving augmentation therapy at the standard dose of 60 mg/kg/week continue to have a significant lung inflammation that may lead to detrimental clinical consequences. This inflammation can be further reduced with higher AAT dosing.

The study will enroll 20 subjects with AATD and COPD already receiving augmentation therapy with any brand at standard doses for at least a month. For inclusion and exclusion criteria see below.

Protocol:

The study will take place over approximately 12 weeks: a month receiving Zemaira at standard dose (60 mg/kg/week), a month at double dose (120 mg/kg/week) and a month at standard dose (60 mg/kg/week). The infusions at standard doses will be done at home and infusions with higher doses will be provided at the study site.

the study involves scheduled blood draws for clinical labs and serum for research samples. At the end of each phase a bronchoscopy will be performed (3 in total) to obtain research samples (lung lavage, brushings and endobronchial biopsies).

The first bronchoscopy after receiving 4 weeks of standard augmentation therapy will assess the "residual" inflammation that may be present despite augmentation therapy. The second bronchoscopy after double dose augmentation therapy phase will be to assess changes (decreases) in inflammatory markers. The third bronchoscopy after resuming standard dosing is to assess if inflammation returned to baseline levels (required for proof of concept).

There will be approximately 9 visits to the study clinic. This study does not include placebo (no active drug) treatment. Besides blood draws and bronchoscopy, the study will include questionnaires, lung function testing and urine sample testings.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or Females aged between 18 and 75 years.
  • Diagnosis of AATD, based on documentation of "at-risk" genotypes such as Pi ZZ, SZ or Znull OR documentation of a pre-therapy AAT level < 11 µM.
  • Evidence of COPD (emphysema or airflow obstruction) with FEV1 < 80%
  • Receiving standard dose of augmentation therapy (with any commercial formulation) for at least 1 month at the dose of 60 mg/kg/week.
  • At least ONE of the following criteria of disease severity:

    • 2 or more acute exacerbations or 1 hospitalization due to respiratory symptoms in the past 12 months. Definition of exacerbations: the use of antibiotics and a course of steroids to treat a flare of pulmonary symptoms, regardless if the subject required emergency room care or hospital admission. The diagnosis of the acute exacerbation will be obtained by direct history obtained from the patient and confirmed by the PI. Attempts should be made to have documentation from the patient's treating physicians, although not required for study entry.
    • St. George Respiratory Questionnaire (SGRQ) total score ≥ 60.
    • Chronic bronchitis: daily or almost daily sputum expectoration at least 3 months of the year for at least 2 consecutive years. The diagnosis of chronic bronchitis will be obtained by direct history obtained from the patient and confirmed by the PI. Attempts should be made to have documentation from the patient's treating physicians, although not required for study entry.
    • Documented FEV1 decline of at least ≥ 60 ml/year for 2 consecutive years while receiving augmentation therapy

Exclusion Criteria:

- Patients unsuitable to have a bronchoscopy due to poor clinical condition as judged by the PI. In general we will exclude subjects with hypoxemia, coagulopathy or FEV1 below 40% predicted.

Note: Subjects with FEV1 values below 40% predicted may be included and reassessed after optimization of therapy. Final determination to include the patient if deemed suitable for the procedure will be determined by the PI before first planned bronchoscopy (regardless of FEV1 value).

  • Patients participating in other clinical trials.
  • Use of chronic antibiotics or oral steroids
  • Continues to smoke
  • Inability to sign informed consent
  • Pregnancy or willing to become pregnant
  • Known IgA deficiency (we will include only patients already receiving augmentation therapy so it will be unlikely to encounter this exclusion criteria)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01669421

Contacts
Contact: Michael A Campos, MD (305)243-6387 mcampos1@med.miami.edu
Contact: Patricia Rebolledo, MD (305) 243-2568 prebolledo@med.miami.edu

Locations
United States, Florida
Division of Pulmonary and Critical Care, Human Reseach, U of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Michael A Campos, MD    305-243-3045    mcampos1@med.miami.edu   
Contact: Patricia Rebolledo, MD    (305)243-5549    prebolledo@med.miami.edu   
Principal Investigator: Michael A Campos, MD         
Sponsors and Collaborators
Michael Campos, MD
CSL Behring
Investigators
Principal Investigator: Michael A Campos, MD University of Miami
  More Information

Publications:
Responsible Party: Michael Campos, MD, Associate Professor, University of Miami
ClinicalTrials.gov Identifier: NCT01669421     History of Changes
Other Study ID Numbers: 20100844
Study First Received: August 14, 2012
Last Updated: January 13, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Miami:
Alpha 1

Additional relevant MeSH terms:
Alpha 1-Antitrypsin Deficiency
Digestive System Diseases
Emphysema
Genetic Diseases, Inborn
Liver Diseases
Lung Diseases
Pathologic Processes
Respiratory Tract Diseases
Subcutaneous Emphysema
Alpha 1-Antitrypsin
Protease Inhibitors
Protein C Inhibitor
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serine Proteinase Inhibitors
Trypsin Inhibitors

ClinicalTrials.gov processed this record on July 29, 2015